You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack ...

Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.

Eli Lilly has escalated its legal offensive against compounding pharmacies accused of selling unauthorized copies of its blockbuster diabetes and weight-loss drugs containing tirzepatide, the active ...

Being first to market with a drug can be crucial. Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country ...

Eli Lilly is throwing legal punches in a pharmaceutical showdown over tirzepatide, its prized ingredient in diabetes and weight-loss treatments. The company filed lawsuits against four ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Please consult our website policy prior to making financial decisions. In a significant advancement for diabetes and weight-loss treatment, Eli Lilly (NYSE: LLY) has unveiled promising trial results ...

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...